Trial Profile
Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Apr 2024
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Cutaneous T-cell lymphoma; Large granular lymphocytic leukaemia; Peripheral T-cell lymphoma; T-cell lymphoma; T-cell prolymphocytic leukaemia
- Focus Therapeutic Use
- 12 Dec 2023 Results (n=23) assessing the efficacy and mechanism of JAK1/2 blockade in Large-granular-lymphocytic-leukaemia, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 23 Mar 2022 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.
- 23 Mar 2022 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2024.